[go: up one dir, main page]

WO2007013359A3 - Cancer related gene rasgef1a - Google Patents

Cancer related gene rasgef1a Download PDF

Info

Publication number
WO2007013359A3
WO2007013359A3 PCT/JP2006/314443 JP2006314443W WO2007013359A3 WO 2007013359 A3 WO2007013359 A3 WO 2007013359A3 JP 2006314443 W JP2006314443 W JP 2006314443W WO 2007013359 A3 WO2007013359 A3 WO 2007013359A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
rasgef1a
methods
related gene
cancer related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2006/314443
Other languages
French (fr)
Other versions
WO2007013359A2 (en
Inventor
Yusuke Nakamura
Yoichi Furukawa
Shuichi Nakatsuru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
University of Tokyo NUC
Original Assignee
Oncotherapy Science Inc
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc, University of Tokyo NUC filed Critical Oncotherapy Science Inc
Priority to EP06781398A priority Critical patent/EP1915462A2/en
Priority to JP2008502063A priority patent/JP2009505631A/en
Publication of WO2007013359A2 publication Critical patent/WO2007013359A2/en
Publication of WO2007013359A3 publication Critical patent/WO2007013359A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides methods for detecting and diagnosing cancer. According to an embodiment, the diagnostic method involves the determination of the expression level of the RASGEF1A gene which was discovered to discriminate cancer cells from normal cells. Furthermore, the present invention provides methods of screening for therapeutic agents useful in the treatment of cancer, methods for treating cancer, and methods for vaccinating a subject against cancer.
PCT/JP2006/314443 2005-07-28 2006-07-14 Cancer related gene rasgef1a Ceased WO2007013359A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06781398A EP1915462A2 (en) 2005-07-28 2006-07-14 Cancer related gene rasgef1a
JP2008502063A JP2009505631A (en) 2005-07-28 2006-07-14 Cancer-related gene RASEGEF1A

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70405405P 2005-07-28 2005-07-28
US60/704,054 2005-07-28

Publications (2)

Publication Number Publication Date
WO2007013359A2 WO2007013359A2 (en) 2007-02-01
WO2007013359A3 true WO2007013359A3 (en) 2007-06-14

Family

ID=37575169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/314443 Ceased WO2007013359A2 (en) 2005-07-28 2006-07-14 Cancer related gene rasgef1a

Country Status (4)

Country Link
EP (1) EP1915462A2 (en)
JP (1) JP2009505631A (en)
CN (1) CN101273145A (en)
WO (1) WO2007013359A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105288659B (en) * 2015-06-01 2019-07-26 北京泱深生物信息技术有限公司 The application of TENM1 gene and its expression product in diagnosis and treatment papillary adenocarcinoma
EP3586866A1 (en) * 2018-06-28 2020-01-01 Universität Zürich Immunodominant proteins and fragments in multiple sclerosis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001059063A2 (en) * 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2002103028A2 (en) * 2001-05-30 2002-12-27 Biomedical Center In silico screening for phenotype-associated expressed sequences
EP1347046A1 (en) * 2002-03-22 2003-09-24 Research Association for Biotechnology Full-length cDNA sequences
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005028676A2 (en) * 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Method of diagnosing breast cancer
WO2005044981A2 (en) * 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001059063A2 (en) * 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2002103028A2 (en) * 2001-05-30 2002-12-27 Biomedical Center In silico screening for phenotype-associated expressed sequences
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
EP1347046A1 (en) * 2002-03-22 2003-09-24 Research Association for Biotechnology Full-length cDNA sequences
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005028676A2 (en) * 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Method of diagnosing breast cancer
WO2005044981A2 (en) * 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE INVITROGEN [online] XP002414657, retrieved from HTTPS://RNAIDESIGNER.INVITROGEN.COM/RNAIEXPRESS/RNAIEXPRESS.DO?LOCUSID=221002 *
MAXWELL G LARRY ET AL: "Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 JUN 2005, vol. 11, no. 11, 1 June 2005 (2005-06-01), pages 4056 - 4066, XP002415036, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
CN101273145A (en) 2008-09-24
WO2007013359A2 (en) 2007-02-01
JP2009505631A (en) 2009-02-12
EP1915462A2 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
WO2005028675A3 (en) Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc)
WO2005029067A3 (en) Method of diagnosing breast cancer
WO2004031412A3 (en) Method for diagnosing pancreatic cancer
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
WO2004031410A3 (en) Method for diagnosing testicular seminomas
WO2004031409A3 (en) Method for diagnosing chronic myeloid leukemia
WO2007013665A3 (en) Method of diagnosing small cell lung cancer
WO2006085684A3 (en) Method of diagnosing bladder cancer
WO2007109236A8 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2010091049A3 (en) Diagnosis and treatment of cancer
MX339340B (en) Methods for predicting and improving the survival of gastric cancer patients.
WO2004031414A3 (en) Method for diagnosing prostate cancer
EP2738265A3 (en) MHC genes and risk of graft versus host disease
WO2005005661A3 (en) Genes regulated in ovarian cancer as prognostic and therapeutic targets
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
WO2009089521A3 (en) Predictors for evaluating response to cancer therapy
WO2004038045A3 (en) Method for diagnosing diffuse-type gastric cancer
WO2014023808A3 (en) Method for evaluating a cancer patient for propensity to respond to a therapy
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
WO2007013360A3 (en) Pancreatic cancer related gene cst6 and gabrp
SG163614A1 (en) Colon cancer related gene tom34
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680035357.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2008502063

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006781398

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06781398

Country of ref document: EP

Kind code of ref document: A2